Kyowa Kirin and Grünenthal collaborate on therapy portfolio by John Pinching | Aug 2, 2023 | News | 0 The deal covers 13 brands across six therapeutic areas, mainly focused on pain treatment Read More
King’s College London and Grünenthal join forces to ease pain by John Pinching | Apr 27, 2023 | News | 0 Duo will collaborate to develop pluripotent stem cell-based microfluidic cultures for pain research Read More
AZ sells rights to statin med Crestor to Grünenthal by Lucy Parsons | Dec 1, 2020 | News | 0 Grünenthal will pay $320m upfront for the rights Read More
AZ divests migraine drug to Grünenthal by Selina McKee | Jun 7, 2017 | News | 0 AstraZeneca has sold global rights (ex Japan) for its migraine drug Zomig to Grünenthal, as it continues to shed products outside of its area of strategic focus. Read More